Oncohema Key

Summary of Key Points • Surgery remains the most effective curative approach for early-stage (IA–IIB) NSCLC. Selected cases with clinical stage IIIA disease equally benefit from radical resection. • Stereotactic…

Summary of Key Points • Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, C-ros oncogene 1 (ROS1), ret proto-oncogene (RET) tyrosine kinase inhibitors (TKIs), several antiangiogenesis agents, and…

Summary of Key Points • Performance status is universally recognized as an independent prognostic factor and typically correlates with the extent of tumor burden. • As first-line therapy, platinum agent…

Summary of Key Points • Immunotherapy has entered a new era in lung cancer and is rapidly changing the standard of care. • Vaccines as monotherapies have shown marginal efficacy…

Summary of Key Points • Treatment of lung cancer is rapidly evolving. Large cell carcinomas as a group have therapeutically relevant driver mutations in nearly 40% of cases. • Despite…

Summary of Key Points • Discussed are tumor factors that affect treatment responses and outcome and host genetic elements that affect drug metabolism. Only pharmacogenomics elements that interact with chemotherapeutic…

Summary of Key Points • Maintenance therapy offers the possibility of continued active treatment to delay disease progression and symptom deterioration and, more importantly, improved overall survival of patients with…

Summary of Key Points • There are a growing proportion of patients who are candidates for second-line therapy and beyond. • Treatment choices are dictated by tumor histology, molecular phenotype…

Summary of Key Points • The acute and late toxicity of radiotherapy (RT) for lung cancer usually involves the lungs, esophagus, and heart. Lung • Post-RT, there are multiple biochemical…